Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
1,498
Views
0
CrossRef citations to date
0
Altmetric
Article

Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest

Alexander Egeberga Department of Dermatology, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, DenmarkView further author information
,
Denis Jullienb Hospices Civils de Lyon, Hôpital E. Herriot, Service de Dermatologie, Université Lyon-1; INSERM Unité, Lyon, FranceView further author information
,
Kristian Gaarn Du Jardinc Almirall R&D, Barcelona, SpainView further author information
&
Diamant Thaçid Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, GermanyCorrespondence[email protected]
View further author information
Article: 2220447 | Received 17 Apr 2023, Accepted 15 May 2023, Published online: 21 Jun 2023

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.